Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies targeting p53 mutations, a key driver in many cancers. This page provides investors and researchers with verified updates on clinical trials, regulatory milestones, and corporate developments.
Access real-time announcements including phase progressions for PC14586 and other pipeline candidates, financial disclosures, and strategic collaborations. Our curated repository ensures you stay informed about PMVP’s tumor-agnostic approach to reactivating p53’s tumor-suppressing function.
Key updates cover clinical data publications, FDA designations, and research partnerships advancing small-molecule therapeutics. Bookmark this page for streamlined access to PMVP’s progress in developing treatments that address unmet needs in genetically defined cancers.
PMV Pharmaceuticals (PMVP) reported its full year 2024 financial results, highlighting progress in its PYNNACLE clinical trial for rezatapopt. The company ended 2024 with $183.3 million in cash and equivalents, providing runway through 2026.
Key developments include:
- Over 90% of sites activated for Phase 2 PYNNACLE trial across global regions
- Interim analysis data expected mid-2025
- New Phase 1b study launched with MD Anderson Cancer Center
- Net loss of $58.7 million in 2024, improved from $69.0 million in 2023
- R&D expenses increased to $58.5 million from $55.9 million
The PYNNACLE Phase 1 trial showed promising results with 7 confirmed partial responses in ovarian cancer patients and 3 in breast cancer patients. However, the company discontinued the combination arm with KEYTRUDA® due to insufficient clinical benefit.
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.
The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.
Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.
PMV Pharmaceuticals reported Q3 2024 financial results and provided updates on its PYNNACLE clinical trial. The Phase 2 portion evaluating rezatapopt as monotherapy is progressing with over 75% of sites activated globally. The company ended Q3 with $197.9 million in cash, providing runway through 2026. Net loss increased to $19.2 million from $16.6 million year-over-year. R&D expenses rose to $16.9 million, while G&A expenses decreased to $4.9 million. The company plans an interim analysis by mid-2025 and anticipates a New Drug Application filing by end of 2026.
PMV Pharmaceuticals provided updates on its PYNNACLE clinical trial for rezatapopt. The Phase 2 monotherapy portion is progressing well, with >75% of sites activated globally and interim analysis expected by mid-2025. However, the company is discontinuing the Phase 1b combination arm with KEYTRUDA due to dose-limiting toxicities and clinical benefit. The maximum tolerated dose was established at rezatapopt 500mg daily with pembrolizumab 200mg every three weeks.
Additionally, PMV announced collaboration with MD Anderson and Memorial Sloan Kettering for a new Phase 1b study evaluating rezatapopt in AML/MDS patients with TP53 Y220C mutation, starting Q1 2025.
PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2024 financial results and provided an update on the PYNNACLE clinical trial. Key points include:
1. Enrollment is on track for the Phase 2 monotherapy portion of PYNNACLE, with over 60% of sites activated across the U.S., Europe, and Asia-Pacific.
2. The company expects an interim analysis from Phase 2 monotherapy by mid-2025 and anticipates an NDA filing by the end of 2026.
3. Cash position of $212.9 million as of June 30, 2024, providing an expected runway to the end of 2026.
4. Net loss for Q2 2024 was $1.2 million, significantly reduced from $17.4 million in Q2 2023 due to the sale of New Jersey accumulated net operating losses.
5. R&D expenses increased to $14.6 million in Q2 2024, while G&A expenses decreased to $5.5 million.
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company, announced participation in two major investor conferences in June 2024. David H. Mack, Ph.D., CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent PMV at the Jefferies Global Healthcare Conference on June 6 and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12. Both sessions will include a fireside chat format. Live audio webcasts and archived replays will be accessible online at the company's Events & Presentations page.
Foundation Medicine and PMV Pharmaceuticals have partnered to develop FoundationOne®CDx, a genomic profiling test, as a companion diagnostic for PMV Pharma’s investigational therapy, rezatapopt. Rezatapopt targets the TP53 Y220C mutation found in about 1% of solid tumors, often deemed undruggable despite its prevalence in 50% of cancers. This collaboration utilizes Foundation Medicine's real-world data and genomic tests to support PMV Pharma's clinical trials. Rezatapopt received Fast Track designation from the FDA and is undergoing Phase 2 trials.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported financial results and corporate highlights for Q1 2024. The company dosed the first patient in the Phase 2 PYNNACLE trial for rezatapopt, a potential treatment for advanced solid tumors. Phase 1 data for rezatapopt in advanced ovarian cancer was presented at the 2024 SGO Annual Meeting. The company ended Q1 with $213.1 million in cash, providing expected cash runway to end of 2026.
